Use of Digital Biomarkers to Track COVID-19 Patients and Predict Outbreaks
Use of RPM Strategies During the Pandemic
Huma
Biofourmis
Oura
Kinsa Health
Scripps Institute DETECT Study
Using Digital Biomarkers to Mitigate the Impact of COVID-19 on Clinical Trials
Impact of COVID-19 Social Distancing Measures on Clinical Trials
Adoption of Virtual Trials During the COVID-19 Crisis
Digitization of Clinical Trials Is Increasing
Key Takeaways
Appendix
Methodology
Abbreviations
Related Reports
About the Authors
About GlobalData About GlobalData

Companies Mentioned
- Medopad (now Huma)
- Biofourmis
- Oura Health
- Kinsa Health
- Scripps Research Translational Institute